• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Recurrent Atherosclerotic Cardiovascular Disease Events Potentially Prevented with Guideline-Recommended Cholesterol-Lowering Therapy following Myocardial Infarction
ConclusionImplementation of guideline-recommended cholesterol-lowering therapy could prevent a substantial percentage of recurrent ASCVD events.
Source: Cardiovascular Drugs and Therapy - April 13, 2023 Category: Cardiology Source Type: research

Medicare Part D Use of Older Medicare Beneficiaries Admitted to Hospice
ConclusionReceipt of medications through Medicare Part D after hospice admission is common, particularly for preventative medications, and varies according to admission diagnosis. Further research aimed at better understanding individual‐, provider‐, and healthcare system–level contributors to nonpalliative medication use in the hospice population is warranted.
Source: Journal of the American Geriatrics Society - February 1, 2018 Category: Geriatrics Authors: Patrick M. Zueger, Holly M. Holmes, Gregory S. Calip, Dima M. Qato, A. Simon Pickard, Todd A. Lee Tags: Clinical Investigation Source Type: research

Impact of Ezetimibe on the Rate of Cardiovascular-Related Hospitalizations and Associated Costs Among Patients With a Recent Acute Coronary Syndrome: Results From the IMPROVE-IT Trial (Improved Reduction of Outcomes: Vytorin Efficacy International Trial) Original Articles
Conclusions— Addition of ezetimibe to statin therapy in patients with a recent acute coronary syndrome leads to reductions in cardiovascular-related hospitalizations and associated costs, with the greatest cost offsets in high-risk patients. These cost reductions may completely offset the cost of the drug once ezetimibe becomes generic, and may lead to cost savings from the perspective of the healthcare system, if treatment with ezetimibe is targeted to high-risk patients. Clinical Trial Registration— URL: https://www.clinicaltrials.gov. Unique Identifier: NCT00202878
Source: Circulation: Cardiovascular Quality and Outcomes - May 15, 2017 Category: Cardiology Authors: Pokharel, Y., Chinnakondepalli, K., Vilain, K., Wang, K., Mark, D. B., Davies, G., Blazing, M. A., Giugliano, R. P., Braunwald, E., Cannon, C. P., Cohen, D. J., Magnuson, E. A. Tags: Secondary Prevention, Cost-Effectiveness, Health Services Original Articles Source Type: research

Racial differences in statin adherence following hospital discharge for ischemic stroke
Conclusions: Compared with white adults, black adults were more likely to be nonadherent to statins following hospitalization for ischemic stroke.
Source: Neurology - May 8, 2017 Category: Neurology Authors: Albright, K. C., Zhao, H., Blackburn, J., Limdi, N. A., Beasley, T. M., Howard, G., Bittner, V., Howard, V. J., Muntner, P. Tags: All Cerebrovascular disease/Stroke ARTICLE Source Type: research

African Americans Are Less Likely to Be Adherent to Statins After Ischemic Stroke: An Analysis of Medicare Beneficiaries Following Hospital Discharge (S4.003)
Conclusions: African Americans may not be obtaining the recurrent stroke prevention therapy provided by statins, possibly contributing to the higher rate of recurrent stroke in this population.Disclosure: Dr. Albright has nothing to disclose. Dr. Blackburn has nothing to disclose. Dr. Zhao has nothing to disclose. Dr. Beasley has nothing to disclose. Dr. Limdi has nothing to disclose. Dr. Howard has nothing to disclose. Dr. Muntner has nothing to disclose.
Source: Neurology - April 3, 2016 Category: Neurology Authors: Albright, K., Blackburn, J., Zhao, H., Beasley, T., Limdi, N., Howard, V., Muntner, P. Tags: Health Disparities and Sex Differences in Stroke Source Type: research

African Americans Are Less Likely to Be Adherent to Statins After Ischemic Stroke: An Analysis of Medicare Beneficiaries Following Hospital Discharge (I2.006)
Conclusions: African Americans may not be obtaining the recurrent stroke prevention therapy provided by statins, possibly contributing to the higher rate of recurrent stroke in this population.Disclosure: Dr. Albright has nothing to disclose. Dr. Blackburn has nothing to disclose. Dr. Zhao has nothing to disclose. Dr. Beasley has nothing to disclose. Dr. Limdi has nothing to disclose. Dr. Howard has nothing to disclose. Dr. Muntner has nothing to disclose.
Source: Neurology - April 3, 2016 Category: Neurology Authors: Albright, K., Blackburn, J., Zhao, H., Beasley, T., Limdi, N., Howard, V., Muntner, P. Tags: Stroke in the Elderly and Young: Challenges for the Next Decade Data Blitz Presentations Source Type: research

Quality of Care and Ischemic Stroke Risk After Hospitalization for Transient Ischemic Attack: Findings From Get With The Guidelines-Stroke Original Articles
Conclusions— TIA patients with high estimated ischemic stroke risk are less likely to receive defect-free care than low-risk patients. Standardized risk assessment and delivery of optimal inpatient care are needed to reduce this risk-treatment mismatch.
Source: Circulation: Cardiovascular Quality and Outcomes - October 29, 2015 Category: Cardiology Authors: O'Brien, E. C., Zhao, X., Fonarow, G. C., Schulte, P. J., Dai, D., Smith, E. E., Schwamm, L. H., Bhatt, D. L., Xian, Y., Saver, J. L., Reeves, M. J., Peterson, E. D., Hernandez, A. F. Tags: Ethics and Policy Original Articles Source Type: research

Clinical Effectiveness of Statin Therapy after Ischemic Stroke: Primary Results from the Statin Therapeutic Area of the Patient-Centered Research into Outcomes Stroke Patients Prefer and Effectiveness Research (PROSPER) Study.
CONCLUSIONS: -In older ischemic stroke patients who were not taking statins at the time of admission, discharge statin therapy was associated with lower risk of MACE and nearly a month more home-time during the 2-year period post-hospitalization. PMID: 26246175 [PubMed - as supplied by publisher]
Source: Circulation - August 5, 2015 Category: Cardiology Authors: O'Brien EC, Greiner MA, Xian Y, Fonarow GC, Olson DM, Schwamm LH, Bhatt DL, Smith EE, Maisch L, Hannah D, Lindholm B, Peterson ED, Pencina MJ, Hernandez AF Tags: Circulation Source Type: research

The Incidence Of Secondary Stroke Prevention Medication Following Hospitalization For Ischemic Stroke (P5.005)
CONCLUSIONS:The incidence of statins and ACE-I/ARB initiation following a stroke, among older adults discharged home was low (24-35%). Reported rates of side effects of either class of medications are not high enough to account for the low observed incidence. Better understanding of why beneficiaries are not receiving SSP, namely statins and ACE-I/ARBs, within 90 days of an ischemic stroke is critical to preventing recurrent stroke.Study Supported by:UnfundedDisclosure: Dr. Blackburn has nothing to disclose. Dr. Zhao has nothing to disclose. Dr. Kilgore has nothing to disclose. Dr. Albright has received research support fr...
Source: Neurology - April 9, 2014 Category: Neurology Authors: Blackburn, J., Zhao, H., Kilgore, M., Albright, K. Tags: Cerebrovascular Disease and Interventional Neurology II Source Type: research

The Incidence Of Secondary Stroke Prevention Medication Following Hospitalization For Ischemic Stroke (I2-1.006)
CONCLUSIONS:The incidence of statins and ACE-I/ARB initiation following a stroke, among older adults discharged home was low (24-35%). Reported rates of side effects of either class of medications are not high enough to account for the low observed incidence. Better understanding of why beneficiaries are not receiving SSP, namely statins and ACE-I/ARBs, within 90 days of an ischemic stroke is critical to preventing recurrent stroke.Study Supported by:UnfundedDisclosure: Dr. Blackburn has nothing to disclose. Dr. Zhao has nothing to disclose. Dr. Kilgore has nothing to disclose. Dr. Albright has received research support fr...
Source: Neurology - April 9, 2014 Category: Neurology Authors: Blackburn, J., Zhao, H., Kilgore, M., Albright, K. Tags: New Antithrombotic Agents for Stroke Prevention Poster Presentations Source Type: research